The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...

Actinium announced ATNM-400, a novel, non-PSMA targeting, first in class radiotherapy for prostate cancer utilizing the Actinium-225 ...

Actinium正在推进ATNM-400的研发，预计将从Pluvicto耐药性前列腺癌模型中获得更多数据。该公司更广泛的研发重点包括几个针对实体瘤适应症的临床前项目，利用其拥有的230项与靶向放射疗法和Ac-225制造相关的专利和专利申请组合。

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced ATNM-400, a novel, non-PSMA targeting, first in ...

Actinium Pharmaceuticals, Inc.  (Actinium or the Company), a pioneer in the development of targeted radiotherapies, announced it will be presenting a business update today at Trump Mar-a-Lago Club, ...

Actinium Pharma inks supply agreement with Eckert & Ziegler for Ac-225 radioisotope to support comprehensive development activities: New York Wednesday, March 26, 2025, 18:00 Hrs ...

EQS-News: Eckert & Ziegler SE / Key word (s): Agreement/Incoming Orders Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities 25.03.2025 / 09:30 ...

Agreement/Incoming OrdersEckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities 25.03.2025 / 09:30 CET/CESTThe issuer is solely responsible for the ...

Investing.com — Actinium制药公司（NYSE AMERICAN: ATNM），一家专注于靶向放射治疗的公司，已从Eckert & Ziegler获得了放射性同位素锕-225（Ac-225）的供应，旨在推进其国内外癌症治疗的临床试验。

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into an agreement for the supply ...

Actinium Pharma inks research pact with Memorial Sloan Kettering to support further clinical expansion of Actimab-A's backbone therapy strategy: New York Saturday, March 22, 2025, ...

The firm will assess whether adding its CD33-targeted radiotherapy Actimab-A to PD-1 inhibitors will benefit patients more than PD-1 inhibitors alone.